Journal abstracts

March 1999
Palliative Medicine;1999, Vol. 13 Issue 2, p173
Academic Journal
Presents an abstract of the paper `The Problem of Weakness in Patients with Advanced Cancer,' by D.J.F. Brown, published in the `International Journal of Palliative Nursing.' Focus on the symptom of weakness as a physical aspect of the weakness-fatigue complex in cancer.


Related Articles

  • Cancer-Induced Cachexia: A Guide for the Oncologist. Gullett, Norleena; Rossi, Peter; Kucuk, Omer; Johnstone, Peter A. S. // Journal of the Society for Integrative Oncology;Fall2009, Vol. 7 Issue 4, p155 

    Cancer-induced cachexia (CIC) is a paraneoplastic syndrome that may account for up to 20% of deaths in cancer patients. Cachexia includes distinct metabolic changes that are the result of an acute-phase response (APR) mounted by the host as a reaction to tumor cells. These changes include...

  • Nutritional Support in Cancer. Costelli, Paola; Muscaritoli, Maurizio; Penna, Fabio; Bonetto, Andrea; Minero, Valerio Giacomo; Aversa, Zaira; Iannuzzi, Silvia; Bonelli, Gabriella; Baccino, Francesco M.; Fanelli, Filippo Rossi // Current Nutrition & Food Science;2007, Vol. 3 Issue 3, p242 

    The management of cancer patients is frequently complicated by the occurrence of cachexia, a complex syndrome characterized by marked depletion of body weight, associated with profound alterations of both nutritional status and metabolic homeostasis. Progressive wasting of skeletal muscle mass...

  • Understanding cachexia in patients with cancer. Holmes, Susan // Nursing Standard;1/26/2011, Vol. 25 Issue 21, p47 

    Cancer cachexia is a progressive wasting syndrome characterised by loss of both adipose tissue and lean body mass. It is a complex metabolic process common in patients with cancer and responsible for death. Consideration of this syndrome is important because of its prevalence and its significant...

  • Fatigue experience in advanced cancer: a phenomenological approach. Potter, Joan // International Journal of Palliative Nursing;Jan2004, Vol. 10 Issue 1, p15 

    This study describes the experience of fatigue in patients with advanced cancer. A phenomenological approach was adopted to allow a fuller expression of the phenomenon of fatigue in the sample of six patients. Five major themes were identified. These were physical, psychological, social and...

  • Sunitinib.  // Reactions Weekly;9/28/2013, Issue 1471, p39 

    The article presents a case study of a man who developed asthenia and neutropenia while being treated with sunitinib for recurrent thyroid cancer.

  • Rehabilitation for elderly patients with cancer asthenia: making a transition to palliative care. Scialla, S.; Cole, R.; Scialla, T.; Bednarz, L.; Scheerer, J. // Palliative Medicine;Mar2000, Vol. 14 Issue 2, p121 

    The transition from curative to palliative care for elderly patients with cancer-related asthenia presents complex challenges to oncologists. A result of this complexity is a lack of regard for the maintenance of physical and mental function. This study examined the effects of comprehensive,...

  • Fatigue et cancer.  // Oncologie;Jul2011, Vol. 13 Issue 7, p346 

    No abstract available.

  • First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer. Aparicio, Jorge; Vicent, José M.; Maestu, Inmaculada; Bosch, Carles; Galán, Antonio; Busquier, Isabel; Llorca, Cristina; Garcerá, Salvador; Campos, Juan M.; López-Tendero, Pedro; Balcells, Miquel // Oncology;2005, Vol. 68 Issue 1, p58 

    Objectives: The combination of irinotecan and raltitrexed is safe and active in 5-fluorouracil-refractory, metastatic colorectal cancer (CRC), with the advantage of its convenient three-weekly schedule. The aim of this multicenter phase II study was to assess its efficacy and toxicity in...

  • Second Line Therapy with Weekly Low-dose Docetaxel for Pretreated Non-Small-Cell Lung Carcinoma Patients: A Multicenter Italian Phase II Study. Ardizzoia, A.; Acquati, M.; Fagnani, D.; Giordano, M.; Visini, M.; Scanni, A.; Quattrone, A.; Fusco, O.; Vergani, C.; Casartelli, C.; Tagliabue, P.; Malugani, F. // Lung;2004, Vol. 182 Issue 1, p1 

    Docetaxel is one of the most active drugs in second-line therapy for non-small-cell-lung-carcinoma (NSCLC). The aim of this multicenter study was to evaluate the safety and efficacy of weekly low-dose docetaxel. Forty-two patients with advanced NSCLC pretreated with cisplatinum-based...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics